PD-1 and PD-L1 inhibitors

View All

pd-and-pd-l1-inhibitors-in-cancer-treatment
PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...

Find More

Delveinsight
PD-1 and PD-L1 inhibitors – Competitive Landscape, Pipeline and Market Analysis, 2015

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...

Find More